• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨髓增生异常综合征:基于连续形态学和细胞遗传学研究的不同演变模式

The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations.

作者信息

Tricot G, Boogaerts M A, De Wolf-Peeters C, Van den Berghe H, Verwilghen R L

出版信息

Br J Haematol. 1985 Apr;59(4):659-70. doi: 10.1111/j.1365-2141.1985.tb07361.x.

DOI:10.1111/j.1365-2141.1985.tb07361.x
PMID:3857071
Abstract

Serial morphological and cytogenetic investigations were performed in 46 patients with the myelodysplastic syndrome (MDS). Twenty-one patients (45.5%) progressed to AML (greater than 30% blasts in bone marrow smears). Based on sequential determinations of percentages of bone marrow blasts, three patterns of evolution were observed in MDS. Patients with evolution pattern A (48%) had an apparently stable disease with minimal or no increase in bone marrow blasts. Exceptionally they developed new or additional chromosomal anomalies during the course of their disease. Cases in this group, who showed no abnormal localization of immature myeloid precursors (ALIP) at time of diagnosis experienced prolonged survival (median: 43 months), while ALIP positive patients had shorter survival times (median: 14 months), with high probability of early death from infections and/or bleeding problems. Patients with evolution pattern B (28%) initially had a morphologically stable disease, comparable to cases with evolution pattern A, but showed an abrupt shift from MDS to AML. Most of these patients (82%) were ALIP positive and a substantial proportion (46%) showed karyotype anomalies at diagnosis. The abrupt shift to AML in these patients was frequently (61.5%) associated with additional cytogenetic anomalies. Patients with evolution pattern C (24%) showed a gradual increase in bone marrow blasts. The majority of these cases (8/11) ultimately developed acute myeloid leukaemia (gradual progression to AML), whereas some patients (3/11) died from infections and/or haemorrhagic complications before they had reached the level of clinical AML. All of these patients were ALIP positive at diagnosis and no additional cytogenetic alterations occurred during evolution. Acquisition of new karyotypic anomalies during the course of MDS was almost invariably associated with abrupt shift to AML. From this retrospective study we conclude that evolution in MDS shows two important aspects, which seem to be preponderant in determining the course and outcome of the disease: one is the proliferative capacity and resulting growth advantage of the neoplastic clone over normal haematopoiesis, as measured by increasing percentages of bone marrow blasts in sequential aspirates; the other one is instability of the clone. Unstable clones have a high propensity to further intraclonal changes; they are expressed morphologically by the abrupt increase in bone marrow blasts and cytogenetically by the acquisition of new or additional karyotype anomalies.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

对46例骨髓增生异常综合征(MDS)患者进行了系列形态学和细胞遗传学研究。21例患者(45.5%)进展为急性髓系白血病(AML)(骨髓涂片原始细胞大于30%)。根据连续测定的骨髓原始细胞百分比,在MDS中观察到三种演变模式。演变模式A的患者(48%)疾病明显稳定,骨髓原始细胞极少增加或无增加。例外的是,他们在病程中出现了新的或额外的染色体异常。该组中诊断时未显示不成熟髓系前体细胞异常定位(ALIP)的患者生存期延长(中位数:43个月),而ALIP阳性患者生存期较短(中位数:14个月),因感染和/或出血问题早期死亡的可能性高。演变模式B的患者(28%)最初疾病形态稳定,与演变模式A的病例相似,但显示从MDS突然转变为AML。这些患者大多数(82%)为ALIP阳性,相当一部分(46%)在诊断时显示核型异常。这些患者向AML的突然转变常(61.5%)与额外的细胞遗传学异常相关。演变模式C的患者(24%)显示骨髓原始细胞逐渐增加。这些病例大多数(8/11)最终发展为急性髓系白血病(逐渐进展为AML),而一些患者(3/11)在达到临床AML水平之前死于感染和/或出血并发症。所有这些患者在诊断时均为ALIP阳性,演变过程中未发生额外的细胞遗传学改变。MDS病程中获得新的核型异常几乎总是与突然转变为AML相关。从这项回顾性研究中我们得出结论,MDS的演变显示出两个重要方面,在决定疾病的进程和结局方面似乎占主导地位:一是增殖能力以及由此产生的肿瘤克隆相对于正常造血的生长优势,通过连续抽吸物中骨髓原始细胞百分比的增加来衡量;另一个是克隆的不稳定性。不稳定克隆极易发生进一步的克隆内变化;它们在形态上表现为骨髓原始细胞突然增加,在细胞遗传学上表现为获得新的或额外的核型异常。(摘要截短至400字)

相似文献

1
The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations.骨髓增生异常综合征:基于连续形态学和细胞遗传学研究的不同演变模式
Br J Haematol. 1985 Apr;59(4):659-70. doi: 10.1111/j.1365-2141.1985.tb07361.x.
2
Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis.骨髓增生异常综合征的预后因素:外周血细胞计数、骨髓细胞学、骨髓活检及染色体分析初始数据的重要性。
Br J Haematol. 1985 May;60(1):19-32. doi: 10.1111/j.1365-2141.1985.tb07381.x.
3
Bone marrow histology in myelodysplastic syndromes. II. Prognostic value of abnormal localization of immature precursors in MDS.骨髓增生异常综合征的骨髓组织学。II. MDS中幼稚前体细胞异常定位的预后价值。
Br J Haematol. 1984 Oct;58(2):217-25. doi: 10.1111/j.1365-2141.1984.tb06079.x.
4
[Analysis on laboratory and clinical characteristics in 65 cases of myelodysplastic syndrome].65例骨髓增生异常综合征患者实验室及临床特征分析
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Dec;17(6):1472-6.
5
Diagnostic criteria for hypocellular acute leukemia: a clinical entity distinct from overt acute leukemia and myelodysplastic syndrome.低细胞性急性白血病的诊断标准:一种与明显急性白血病和骨髓增生异常综合征不同的临床实体。
Leuk Res. 1996 Jul;20(7):563-74. doi: 10.1016/0145-2126(95)00136-0.
6
The rate of disease progression predicts the quality of remissions following intensive chemotherapy for myelodysplastic syndromes.疾病进展速度可预测骨髓增生异常综合征强化化疗后的缓解质量。
Leuk Res. 1994 Nov;18(11):797-804. doi: 10.1016/0145-2126(94)90158-9.
7
Cytogenetic clonality analysis: typical patterns in myelodysplastic syndrome and acute myeloid leukaemia.细胞遗传学克隆性分析:骨髓增生异常综合征和急性髓系白血病的典型模式
Br J Haematol. 1996 Jun;93(3):594-600. doi: 10.1046/j.1365-2141.1996.d01-1692.x.
8
Sequential karyotypic evolutions and bone marrow aplasia preceding acute myelomonocytic transformation from myelodysplastic syndrome.骨髓增生异常综合征急性粒单核细胞转化之前的连续核型演变和骨髓再生障碍
Br J Haematol. 1984 Sep;58(1):53-60. doi: 10.1111/j.1365-2141.1984.tb06058.x.
9
ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.ASXL1 突变作为伴骨髓增生异常相关改变和正常核型的急性髓系白血病的替代标志物。
Cancer Med. 2020 Jun;9(11):3637-3646. doi: 10.1002/cam4.2947. Epub 2020 Mar 26.
10
Abrupt evolution of Philadelphia chromosome-positive acute myeloid leukemia in myelodysplastic syndrome.骨髓增生异常综合征中费城染色体阳性急性髓系白血病的急剧演变。
Eur J Haematol. 2013 Mar;90(3):245-9. doi: 10.1111/ejh.12056. Epub 2013 Jan 9.

引用本文的文献

1
Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions.骨髓增生异常综合征(MDS)及潜在的MDS前期病症的拟议最低诊断标准。
Oncotarget. 2017 Jul 5;8(43):73483-73500. doi: 10.18632/oncotarget.19008. eCollection 2017 Sep 26.
2
The evaluation of the outcome in myelodysplastic patients by using non-cytogenetic prognostic scores.使用非细胞遗传学预后评分对骨髓增生异常综合征患者的预后进行评估。
J Med Life. 2014 Sep 15;7(3):335-8. Epub 2014 Sep 25.
3
Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia.
伴有 IPSS 定义的低危骨髓增生异常综合征患者细胞遗传学异常的获得与不良预后和向急性髓系白血病转化相关。
Am J Hematol. 2013 Oct;88(10):831-7. doi: 10.1002/ajh.23513. Epub 2013 Jul 23.
4
Transformation of myelodysplastic syndrome to acute lymphoblastic leukemia: a case report and review of the literature.骨髓增生异常综合征转化为急性淋巴细胞白血病:一例报告并文献复习
Int J Hematol. 2004 Feb;79(2):147-51. doi: 10.1532/ijh97.03137.
5
Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS).骨髓增生异常综合征(MDS)的发病机制、分类及治疗
Wien Klin Wochenschr. 2003 Aug 14;115(13-14):515-36. doi: 10.1007/BF03041035.
6
Two independent clones in myelodysplastic syndrome following treatment of acute myeloid leukemia.急性髓系白血病治疗后骨髓增生异常综合征中的两个独立克隆。
Int J Hematol. 2002 Feb;75(2):182-6. doi: 10.1007/BF02982025.
7
Myelodysplastic syndromes in childhood: description of seven cases.儿童骨髓增生异常综合征:7例病例描述。
Ann Hematol. 1994 May;68(5):241-5. doi: 10.1007/BF01737424.
8
Cytogenetic findings in 179 patients with myelodysplastic syndromes.179例骨髓增生异常综合征患者的细胞遗传学研究结果。
Ann Hematol. 1995 Apr;70(4):171-87. doi: 10.1007/BF01700373.
9
FAB classification of myelodysplastic syndromes: merits and controversies.骨髓增生异常综合征的FAB分类:优点与争议
Ann Hematol. 1995 Jul;71(1):3-11. doi: 10.1007/BF01696227.
10
Comparison of scoring systems in primary myelodysplastic syndromes.原发性骨髓增生异常综合征评分系统的比较
Ann Hematol. 1995 Jun;70(6):301-8. doi: 10.1007/BF01696616.